Chronic Lymphocytic Leukemia Therapeutics Market Forecast Study 2022

Increasing Drug Approvals For Treatment of Cll (Chronic Lymphocytic Leukemia)

The growth of chronic lymphocytic leukemia therapeutics market is enhanced by increasing new drug approvals for its treatment. For instance,

On April 21, 2020 the Food and Drug Administration (FDA), USA approved Imbruvica (ibrutinib) in combination with rituximab for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval marked the the 11th FDA approval for Imbruvica (ibrutinib) since it was first approved in 2013 and the sixth in CLL, the most common form of leukemia in adults.

In 2020, CDER approved Inqovi (decitabine and cedazuridine)tablets, for treatment of adult patients with the blood cancers, myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia. 

On May 15, 2019, the Food and Drug Administration approved venetoclax (VENCLEXTA, AbbVie Inc. and Genentech Inc.) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

In November 2019, AstraZeneca received the US Food and Drug Administration (FDA) approval for Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). The US approval was granted under the FDA’s Real-Time Oncology Review and newly established Project Orbis programmes.

Hence, such new regulatory approvals for new drugs is expected to boost the chronic lymphocytic leukemia therapeutics market.

Rise In Prevalence Of Chronic Lymphocytic Leukaemia

The rise in prevalence of chronic lymphocytic leukemia (CLL) is leading to increase in demand for treatment, hence driving the growth of CLL therapeutics market.

For instance, as per the American Cancer Society and National Cancer Institute estimates, in 2021, it is estimated that there will be 21,250 new cases of chronic lymphocytic leukemia and an estimated 4,320 people will die of this disease.

Chronic lymphocytic leukemia is more common in adults and more common among men than women, particularly white men. The rate of new cases of chronic lymphocytic leukemia was 4.9 per 100,000 men and women per year based on 2014–2018 cases, age-adjusted.

The rate of new cases of chronic lymphocytic leukemia was 4.9 per 100,000 men and women per year. The death rate was 1.1 per 100,000 men and women per year. These rates are age-adjusted and based on 2014–2018 cases and 2015–2019 deaths.

Approximately 0.6 percent of men and women will be diagnosed with chronic lymphocytic leukemia at some point during their lifetime, based on 2016–2018 data.

In 2018, there were an estimated 195,129 people living with chronic lymphocytic leukemia in the United States.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com